Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2005
06/16/2005WO2005053691A2 Nicotine delivery product and method for producing it
06/16/2005WO2005053690A1 Use of benzimidazole derivatives for the manufacture of a medicament for treating a cancer
06/16/2005WO2005053689A2 Pharmaceutical compositions comprising lercanidipine
06/16/2005WO2005053687A1 Combination of organic compounds
06/16/2005WO2005053686A1 Indolinone based protein kinase inhibitors
06/16/2005WO2005053685A1 Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive drugs
06/16/2005WO2005053684A1 Association of antimicrobial compounds with surfaces and polymers
06/16/2005WO2005053683A1 A method of preventing or treating glaucoma
06/16/2005WO2005053682A2 Use of beta-lapachone for protecting against radiation injury
06/16/2005WO2005053681A2 Novel uses of mevalonate pathway blockers
06/16/2005WO2005053680A1 Combination of 2,3-dibenzylbutyrolactone and licochalcone-a
06/16/2005WO2005053679A1 Novel use of silymarin and the composition comprising the same
06/16/2005WO2005053678A1 Therapeutic or preventive agents for ischemic neuropathy
06/16/2005WO2005053677A1 Use of partricin derivatives for treating fungal and protozoal infections
06/16/2005WO2005053676A1 Use of pentadienoic acid derivatives for the treatment of hyperuricemia
06/16/2005WO2005053675A1 A composition comprising the alcohol compound isolated from the extract of cucurbitaceae family plant having anti-adipogenic and anti-obesity activity
06/16/2005WO2005053674A1 Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity
06/16/2005WO2005053673A1 Use of desoxypeganine for the treatment of schizophrenic psychoses
06/16/2005WO2005053672A1 Remedy for pruritus comprising cilomilast or salt thereof as the active ingredient
06/16/2005WO2005053671A1 Mmp-9 inhibitor containing caffeic acid or caffeic acid phenethyl ester
06/16/2005WO2005053670A1 Ppar agonists for the treatment of hcv infection
06/16/2005WO2005053668A1 Use of bapta derivative for the manufacture of clinical medicament
06/16/2005WO2005053667A1 Novel use of peptide compounds for treating central neuropathic pain
06/16/2005WO2005053666A1 Sprayable composition for the administration of vitamin d derivatives
06/16/2005WO2005053665A1 Treating infectious diseases using ice inhibitors
06/16/2005WO2005053662A1 Dna damage repair inhibitors for treatment of cancer
06/16/2005WO2005053661A2 Pharmaceutical combinations
06/16/2005WO2005053660A2 Pharmaceutical compositions comprising danazol
06/16/2005WO2005053659A1 An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
06/16/2005WO2005053658A1 Butylphthalide soft gel capsule and its preparatin procedure
06/16/2005WO2005053657A2 Coated tablet containing venlafaxin or its salts with controlled release
06/16/2005WO2005053656A1 Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
06/16/2005WO2005053655A1 Method for making pharmaceutical multiparticulates
06/16/2005WO2005053654A1 Controlled release dosage forms of azithromycin
06/16/2005WO2005053653A1 Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
06/16/2005WO2005053652A1 Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
06/16/2005WO2005053650A1 Azithromycin dosage forms with reduced side effects
06/16/2005WO2005053648A1 Pre-metered dry powder inhaler for moisture-sensitive medicaments
06/16/2005WO2005053647A1 Medical product containing tiotropium
06/16/2005WO2005053646A1 Inhalable tiotropium and container therefor
06/16/2005WO2005053645A1 Method for administration tiotropium
06/16/2005WO2005053644A1 A medical product comprising tiotropium in a moisture-proof container
06/16/2005WO2005053643A1 Liposome
06/16/2005WO2005053641A1 Patch
06/16/2005WO2005053640A2 Azithromycin multiparticulate dosage forms by liquid-based processes
06/16/2005WO2005053639A2 Controlled release multiparticulates formed with dissolution enhancers
06/16/2005WO2005053637A2 Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin
06/16/2005WO2005053628A1 Use of osteopontin in dental formulations
06/16/2005WO2005053616A2 Antimicrobial composition
06/16/2005WO2005053614A2 Advanced indolinone based protein kinase inhibitors
06/16/2005WO2005053613A2 Combinations for the treatment of fungal infections
06/16/2005WO2005053610A2 Diamine and iminodiacetic acid hydroxamic acid derivatives
06/16/2005WO2005053609A2 Methods of nad+-dependent deacetylase inhibitors
06/16/2005WO2005053607A2 Method for preventing hepatic encephalopathic episodes
06/16/2005WO2005053605A2 Therapeutic liposomes
06/16/2005WO2005053587A1 Methods and compositions for deterring abuse of opioid containing dosage forms
06/16/2005WO2005053435A1 Preparations for oral and/or topical application
06/16/2005WO2005053427A1 Companion animal compositions comprising short chain oligofructose
06/16/2005WO2005053415A1 Package drink
06/16/2005WO2005053398A1 Antimicrobial compositions comprising polymeric stabilizers
06/16/2005WO2005044818A3 Imidazo[1,2-a]pyridine anxiolytics
06/16/2005WO2005040150A3 Glutamine fructose-6-phosphate amidotransferase (gfat) inhibitors
06/16/2005WO2005040116A3 Indolinone derivatives and their use in treating disease-states such as cancer
06/16/2005WO2005039642B1 Dna delivery with gemini cationic surfactants
06/16/2005WO2005039626A3 Use of hydroxylated amino acids for treating diabetes
06/16/2005WO2005038009A3 Production of tacrolimus (fk-506) using new streptomyces species
06/16/2005WO2005037928A3 Compounds for dual photodiagnosis and therapy
06/16/2005WO2005037832A3 Azabicycyclic compounds for relieving pain and treating central nervous system disorders
06/16/2005WO2005037200A3 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
06/16/2005WO2005037064A3 Use of mannan from saccharomyces cerevisiae for the treatment of asthma
06/16/2005WO2005034883A3 A method of healing skin wounds in mammals and a composition therefor
06/16/2005WO2005033074A3 Salts and polymorphs of a potent antidiabetic compound
06/16/2005WO2005032559A8 Nitric oxide donating derivatives for the treatment of cardiovascular disorders
06/16/2005WO2005032481A3 Quinazoline derivatives as medicaments
06/16/2005WO2005028481A3 Fused pentacyclic polyethers
06/16/2005WO2005028479A3 Hiv replication inhibiting purine derivatives
06/16/2005WO2005027850A3 Treating or preventing restless legs syndrome using prodrugs of gaba analogs
06/16/2005WO2005027832A3 Edta containing compositions and uses thereof
06/16/2005WO2005027636A3 Improved topical treatment for the eradication and/or control of ectoparasites
06/16/2005WO2005025540A3 Mucoactive agents for treating a pulmonary disease
06/16/2005WO2005023778A3 Process for preparation of rosuvastatin calcium
06/16/2005WO2005023305A3 Modulating cell activity by using an agent that reduces the level of cholesterol within a cell
06/16/2005WO2005023227A3 Nicotine formulations and use thereof
06/16/2005WO2005023179A3 Combination methods of treating cancer
06/16/2005WO2005021544A3 N3-substituted imidazopyridine-derivatives as c-kit inhibitors
06/16/2005WO2005020976A3 Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
06/16/2005WO2005020962A8 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
06/16/2005WO2005020840A3 Composition and method for marking procaine penicillin
06/16/2005WO2005018650A3 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent
06/16/2005WO2005018532A3 Purine receptor binding compounds
06/16/2005WO2005016326A3 Analogs of thalidomide as potential angiogenesis inhibitors
06/16/2005WO2005016255A3 Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds
06/16/2005WO2005013937A3 Novel compositions of sildenafil free base
06/16/2005WO2005013892A3 Hydrolytically-resistant boron-containing therapeutics and methods of use
06/16/2005WO2005012278A3 Process for purifying citalopram using polybasic acids
06/16/2005WO2005011592A3 Substituted indazole-o-glucosides
06/16/2005WO2005010051A3 Heparin-derived oligosaccharide mixtures, preparation thereof and pharmaceutical compositions containing said mixtures
06/16/2005WO2005009388A3 Antiglucocorticoids for the treatment of catatonia
06/16/2005WO2005009381A3 Immediate-release formulation of acid-labile pharmaceutical compositions
06/16/2005WO2005009144A8 Pulverulent phytosterol formulations
1 ... 4648 4649 4650 4651 4652 4653 4654 4655 4656 4657 4658 4659 4660 4661 4662 4663 4664 4665 4666 4667 4668 ... 7860